The FDA approved the first treatment ever for Sanfilippo syndrome type A on Thursday, Ultragenyx's gene therapy Fayuvi, and the approval carries a significance beyond the families it directly affects. Sanfilippo type A is an ultra-rare, fatal childhood disorder in which children develop normally for a few years and then lose language, cognition, and movement in a steady regression that most do not survive past their mid-teens. Until today, care was symptom management. There was no disease-modifying therapy at all.
Fayuvi, known in development as UX111 and now with the generic name rebisufligene etisparvovec-hopf, is a one-time intravenous gene therapy. An engineered AAV9 virus carries a working copy of the SGSH gene into cells, letting them make the sulfamidase enzyme the disease is missing, which clears the toxic heparan sulfate that accumulates in the brain. The approval is a full approval, not an accelerated one, and it arrived roughly a year after a manufacturing-related rejection letter nearly ended the program.
The disease the therapy targets
Sanfilippo syndrome type A, formally mucopolysaccharidosis type IIIA, is caused by variants in the SGSH gene that leave children unable to break down heparan sulfate. The substance accumulates in the brain and the body, and the damage shows up as developmental regression: a child who was learning words stops speaking them, a child who was running loses the ability to walk, and the decline continues until the disease is fatal. An estimated 3,000 to 5,000 people in the developed world live with the condition, and the median life expectancy is around 15 years.
The cruelty of the disease is its timing. Children are born looking healthy and develop normally through early childhood, which means families spend the first years of the diagnosis watching for the first signs of what they know is coming. The window in which a therapy can help is the window before regression, and the approval's fine print is built around exactly that: Fayuvi is approved for children with preserved neurodevelopmental function. The therapy cannot undo the damage already done. It exists to keep the damage from happening.
That framing matters for how the approval should be read. This is not a cure, and it is not a reversal for the children who have already lost function. It is a treatment that, in the clinical trial, kept younger children on their developmental trajectory instead of falling off it, and slowed the slide in older children. For a disease with nothing, that is a profound step. It is also, stated plainly, not the end of the disease.
What the trial showed
The approval rests on an open-label, single-arm study in pediatric patients, most between two and five years old, compared against an untreated natural history cohort rather than a placebo group. The design is the story within the story. In a disease this rare, where every patient's decline is documented and predictable, a placebo-controlled trial would have been nearly impossible to run and arguably unethical to ask families to accept, and the natural history comparison is the field's answer to that problem.
In the 17 younger, earlier-stage children, the treatment effect on the Bayley cognitive score was 23.2 points versus natural history, a statistically unambiguous difference, with gains in receptive and expressive language and motor function as well. In the 10 older, more advanced children, the results were the retention of what they had: all 10 kept the ability to communicate, 9 of 10 stayed walking independently, and 9 of 10 kept feeding themselves orally, outcomes that exceed the typical decline in that group.
The biomarker data aligned with the clinical story. Cerebrospinal fluid heparan sulfate fell by a median of about 64 percent from baseline, with follow-up now extending up to 8.5 years, median 4.8. The longest-followed children are the evidence that the enzyme keeps working, and the retention of function in the older group is the evidence that the therapy is doing more than moving a lab value.
The safety profile and what the label asks of families
The therapy is not gentle, and the label is explicit about it. Common adverse reactions include elevated liver enzymes, nausea, vomiting, fever, decreased appetite, low blood counts, and elevated amylase. The label warns of thrombotic microangiopathy, a serious blood-clotting complication known from other AAV gene therapies, and carries the theoretical long-term tumor risk that comes with any therapy that inserts genetic material into cells. Children need corticosteroid prophylaxis starting the day before infusion and continuing at least eight weeks after, and the infusion must happen in a center equipped to manage reactions.
None of this is unusual for systemic gene therapy, and none of it is trivial. The families who have waited for this approval are now weighing a one-time treatment with real short-term risks against a disease whose long-term course is known and uniformly fatal. The label's honest accounting of the risks is the standard the FDA applied, and it is the standard a full approval implies: the benefit is established, the risks are disclosed, and the decision belongs to the family and the treating team.
The manufacturing history is also part of the story families should know. The FDA issued a complete response letter in July 2025 over manufacturing issues, and the resubmission was accepted under priority review with a decision date of September 19. The approval came two days early, and the therapy is manufactured entirely in the United States, in Massachusetts and Ohio. Ultragenyx says commercial product should reach the qualified treatment centers within 30 to 60 days, which means the first approved children will be treated this fall.
What the approval validates beyond this disease
The FDA's decision is the strongest regulatory endorsement yet of the natural-history-comparison design for ultra-rare diseases. The agency had previously signaled openness to the approach, but a full approval based on it, with follow-up stretching toward a decade, sets a precedent that the field's other ultra-rare programs will build on. For diseases too rare for placebo trials, the choice has been between no trial at all and a trial the agency might not accept. Fayuvi's approval says the natural history path leads somewhere.
The approval also validates systemic AAV9 delivery as a route to the central nervous system, the question that hung over the whole class. Getting a gene therapy across the blood-brain barrier without surgery was the field's central technical bet, and Fayuvi's biomarker and clinical data are evidence that the route works in children. Other CNS gene therapy programs will read this approval as permission to continue, and the next decade of ultra-rare neurology development will run, in part, on the path this approval opened.
The Priority Review Voucher the approval carries is the quieter economic signal. The voucher, which Ultragenyx can use or sell, is the policy mechanism that has made rare pediatric drug development financially rational, and it means this approval will partially subsidize the next set of ultra-rare programs. The system's design is doing what it was built to do: a fatal childhood disease with 3,000 to 5,000 patients in the developed world now has a therapy, and the mechanism that rewards that work is firing.
The honest close
The approval's meaning depends on where a family sits. For a family whose child has already lost language and mobility, Fayuvi arrives too late for what it can do, and the label says so. For a family whose child was diagnosed early and is still developing, the approval changes the diagnosis from a death sentence with a known timeline to a treatment decision with real tradeoffs. For the field, it is proof that the ultra-rare disease model, natural history trials, systemic gene delivery, priority review economics, can produce an approval end to end.
The children who were treated in the trial are now the longest-running evidence of what the therapy does, with some followed past eight years. They will keep being the evidence. The approval is the beginning of the learning, not the end of it, and the honest statement of the day is the one the FDA and the company both made: for the first time, there is something to offer. The next chapter is what happens when the first commercially treated children reach the ages the trial cohort has already passed.
Primary sources
- FDA press announcement for the approval, the indication, and the agency's description of the therapy.
- STAT News for the trial design, the natural history comparison, and the disease context.
- Ultragenyx announcement for the efficacy figures, the safety profile, and the manufacturing and distribution plans.